Gastroenterology
Volume 132, Issue 1 , Pages 45-51, January 2007

Chronic Intestinal Pseudo-Obstruction due to Buserelin-Induced Formation of Anti-GnRH Antibodies

  • Bodil Ohlsson

      Affiliations

    • Department of Clinical Sciences, Gastroenterology Division, Malmö University Hospital, Lund University, Malmö, Sweden
  • ,
  • Béla Veress

      Affiliations

    • Department of Laboratory Medicine, Pathology Division, Malmö University Hospital, Lund University, Malmö, Sweden
  • ,
  • Sabina Janciauskiene

      Affiliations

    • Department of Clinical Sciences, Gastroenterology Division, Malmö University Hospital, Lund University, Malmö, Sweden
  • ,
  • Agneta Montgomery

      Affiliations

    • Department of Surgery, Malmö University Hospital, Lund University, Malmö, Sweden
  • ,
  • Monica Haglund

      Affiliations

    • Department of Laboratory Medicine, Pathology Division, Malmö University Hospital, Lund University, Malmö, Sweden
  • ,
  • Anders Wallmark

      Affiliations

    • Department of Clinical Sciences, Gastroenterology Division, Malmö University Hospital, Lund University, Malmö, Sweden
    • Corresponding Author InformationAddress requests for reprints to: Anders Wallmark, MD, PhD, Department of Clinical Sciences, Malmö University Hospital, Entrance 35, S-205 02 Malmö, Sweden. fax: (46) 40337041.

Received 27 December 2005; accepted 5 October 2006.

Background & Aims: A 30-year-old woman, treated with buserelin, an analogue of gonadotropin-releasing hormone (GnRH) (also called luteinizing hormone-releasing hormone, LH-RH), developed chronic intestinal pseudo-obstruction (CIPO). The sudden onset of this disease in a previously healthy woman perplexed us. CIPO refers to a gastrointestinal disorder that can have a variety of causes, such as drugs, among others. Thus, we wanted to examine whether in this patient the development of CIPO is related to the treatment with buserelin. Methods: The patient was examined using esophagogastroduodenoscopy, esophageal, and antroduodenojejunal manometry, gastric emptying tests, and histologic analyses and immunohistochemistry on full-thickness biopsies including staining with anti-GnRH antibody. Plasma samples were examined by the standard serologic analyses and specifically for the occurrence of anti-GnRH antibodies by enzyme-linked immunosorbent assay methods. Results: CIPO was diagnosed based on symptoms (abdominal pain, vomiting, and constipation), and the results of the clinical examinations, such as signs of esophageal aperistalsis, delayed gastric emptying, and small intestinal bursts. Histologic examination revealed a decreased number of myenteric neurons as well as increased neuronal degeneration and an abnormal immune profile. There was a loss of GnRH-containing neurons. The patient had high plasma titers of anti-GnRH antibodies, which occurred on the occasions of the treatment with buserelin. Conclusions: Our findings suggest that the patient has developed CIPO due to buserelin-induced formation of anti-GnRH antibodies destroying GnRH-producing neurons of the myenteric plexus.

Abbreviations used in this paper: CIPO, chronic intestinal pseudo-obstruction, ELISA, enzyme-linked immunosorbent assay, GnRH, gonadotropin releasing hormone, ICCs, interstitial cells of Cajal, IVF, in vitro fertilization, LH-RH, luteinization hormone-releasing hormone

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the Lundström Foundation and the Swedish Research Council. Dr B. Ohlsson was supported by a personal unrestricted grant from the Novo Nordic Foundation.

PII: S0016-5085(06)02270-0

doi:10.1053/j.gastro.2006.10.036

Gastroenterology
Volume 132, Issue 1 , Pages 45-51, January 2007